Comparable serologic responses to 2 different combinations of inactivated hepatitis A virus vaccines in HIV-positive patients during an acute hepatitis A outbreak in Taiwan

7Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

We evaluated the serologic responses to different 2-dose combinations of the inactivated hepatitis A virus (HAV) vaccines Havrix and Vaqta among human immunodeficiency virus-positive individuals during an acute hepatitis A outbreak in Taiwan. In this 16-month retrospective study, one group received 1 dose of Havrix followed by 1 dose of Vaqta, and another group received 2 doses of Vaqta. The Havrix-Vaqta and Vaqta-Vaqta groups achieved similar seroconversion rates at weeks 28-36 (82.3% and 80.9%, respectively; absolute difference, 1.3% [95% confidence interval {CI}, −6.3%-3.7%]) and week 48 (94.7% and 94.4%, respectively; absolute difference, 0.3% [95% CI, −2.6%-3.2%]), suggesting the interchangeability of different combinations of HAV vaccines. The significantly higher seroconversion rate after the first dose of Vaqta, compared with the dose of Havrix (53.0% vs 32.4%) may provide potential benefits in preventing HAV infection during the outbreak.

Cite

CITATION STYLE

APA

Lin, K. Y., Hsieh, S. M., Sheng, W. H., Lo, Y. C., Chuang, Y. C., Cheng, A., … Chang, S. C. (2018). Comparable serologic responses to 2 different combinations of inactivated hepatitis A virus vaccines in HIV-positive patients during an acute hepatitis A outbreak in Taiwan. Journal of Infectious Diseases, 218(5), 734–738. https://doi.org/10.1093/infdis/jiy224

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free